Cetuximab Outperforms Durvalumab in Head and Neck Cancer Treatment: Study Insights

Head and neck cancers rank as the seventh most common type of cancer worldwide, with smokers, drinkers, and individuals with HPV infections being particularly affected. The chemotherapy drug cisplatin is the gold standard for treating these cancers but poses severe side effects, preventing over 30% of patients, especially older adults and those with kidney issues or hearing loss, from using it.

An alternative drug, cetuximab, is often prescribed in these cases, though it is not as effective as cisplatin. Currently, there is no established standard for treating patients who cannot receive cisplatin. Researchers, including Dr. Loren Mell from UC San Diego, are exploring durvalumab, an immune checkpoint inhibitor, as a potentially safer option than cetuximab.

In a clinical trial involving 186 patients with advanced head and neck squamous cell carcinoma ineligible for cisplatin, researchers compared the effectiveness of durvalumab and cetuximab combined with radiation therapy. The results, published in The Lancet Oncology, revealed that cetuximab had a better performance than durvalumab. The trial was halted early due to these findings.

According to Dr. Mell, the two-year survival rate was approximately 64% for cetuximab compared to 51% for durvalumab, showing no advantage for durvalumab. This unexpected outcome suggested that cetuximab might become the new standard of care for patients who cannot use cisplatin. The study also indicated that cetuximab’s efficacy did not depend on whether a patient’s cancer was HPV-related.

Mell emphasized that radiation combined with cetuximab offers a strong alternative for patients who cannot take cisplatin. Many individuals in this group, often older and with additional health concerns, have historically been neglected in clinical trials.

Future research will compare cetuximab against other treatments like carboplatin and paclitaxel, with new trials in development. Ongoing studies aim to evaluate other innovative therapies alongside radiotherapy, creating more options for patients.

The study included contributions from various experts across multiple institutions, underlining a collaborative effort in advancing cancer treatment. Funding came in part from the National Cancer Institute.

For a detailed read on the findings, visit the University of California – San Diego’s website or refer to the publication in The Lancet Oncology.